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Abstract: Type-I interferons (IFN-I) play an important role in the innate immune response 
to several retroviruses. They seem to be effective in controlling the in vivo infection, 
though many of the clinical signs of retroviral infection may be due to their continual 
presence which over-stimulates the immune system and activates apoptosis. IFN-I not only 
affect the immune system, but also operate directly on virus replication. Most data suggest 
that the in vitro treatment with IFN-I of retrovirus infected cells inhibits the final stages of 
virogenesis, avoiding the correct assembly of viral particles and their budding, even though 
the mechanism is not well understood. However, in some retroviruses IFN-I may also act 
at a previous stage as some retroviral LTRs posses sequences homologous to the IFN-
stimulated response element (ISRE). When stimulated, ISREs control viral transcription. 
HIV-1 displays several mechanisms for evading IFN-I, such as through Tat and Nef. 
Besides IFN-α and IFN-β, some other type I IFN, such as IFN-τ and IFN-ω, have potent 
antiviral activity and are promising treatment drugs. 
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1. Retroviruses 
Retroviruses are enveloped viruses, with single stranded RNA, and with an unusual replication 
strategy through a double stranded DNA intermediary. This process is accomplished thanks to the 
enzyme reverse transcriptase, which directs the synthesis of DNA. Once as DNA, the nucleic acid 
integrates in the genome of the host cell, where it behaves as another gene. Retroviral particles are 
surrounded by an envelope, which contains two types of viral glycoproteins: SU (surface) and TM 
(transmembrane); under the envelope the matrix proteins (MA) confer stability to the viral particle. 
The core or capsid is mostly formed by capsid proteins (CA); it lodges inside the RNA surrounded by 
the proteins of the nucleocapsid (NC), and the enzymatic proteins: protease (PR), retrotranscriptase or 
reverse transcriptase (RT) and integrase (IN). Some viruses also have the enzyme dUTPase (DU). 
Viral particles have two identical copies of the ARN genome, which have a cap sequence in the 5’ 
end and a polyadenylated tract or poli(A) in the 3’ end, but do not function as mRNA. Four genes are 
necessary for infectious viruses: gag, pro, pol and env (Figure 1). Gene gag (group specific antigen) 
codes for the structural internal proteins of the virus (MA, CA, NC and other proteins specific to 
certain viruses with undetermined function).  Enzymatic proteins necessary for viral replication are 
coded by genes pro (protease, PR). and pol (polymerase, IN, RT and, in some retroviruses, DU). In 
some retroviruses, pro is in the same ORF as either gag or pol. Gene env (envelope) codes for the 
proteins present in the envelope (SU and TM). Deltaretroviruses, such as human T-cell leukemia virus 
(HTLV) or bovine leukemia virus (BLV) have two additional genes, tax and rex [100], whereas 
lentiviruses posses, besides the mentioned genes, other genes (such as tat, rev, vif, vpr, and others) 
which encode for non-structural proteins relevant for the regulation of expression, viral replication, 
pathogenesis, etc [100]. 
Depending on the virus, virions attach to a number of different specific cellular receptors via their 
envelope glycoproteins. In most cases, the virus envelope and the cell membrane fuse, allowing the 
virion core to enter the cytoplasm; in fewer instances, entry involves receptor-mediated endocytosis. 
Decapsidation, mediated by membrane proteases or by lytic enzymes in the phagolysosomes, is almost 
immediate. Thanks to the RT, a dsDNA molecule is synthesized using the RNA as template. During 
this stage, the RT adds 300-1200 base pairs (bp) in each end of the nucleic acid, which become the 
structures known as Long Terminal Repeats (LTRs, see below). The new dsDNA molecule crosses the 
nuclear membrane, and integrates (by ways of the viral integrase) in the chromosomal DNA of the host 
cell. Initially it was believed that this process happened mostly at random, but nowadays it is 
recognized that different retroviruses display strong preferences in selecting their target sites in the 
genomes of their host cells [for a review, see 22]. For instance, murine leukemia virus (MuLV) prefers 
to integrate at transcription start sites, and human immunodeficiency virus (HIV)-1 displays a strong 
preference for highly active genes [130]. Many of the biological characteristics of retroviruses, such as 
the activation of oncogenes, or the possibility that retroviruses become endogenous and be transmitted 
through generations as Mendelian genes, derive from this stage. When the viral genome is integrated in 
the genome of the host cell it is termed “provirus”. 
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Figure 1. A) Schematic representation of the genomic structure of HIV-1, B) Blow-up of 
the two Long Terminal Repeats (LTR) which flank the proviral sequence, C) Some of the 
regulatory elements in the 5’ LTR, showing the sequence of the Interferon-Stimulated 
Response Elements (ISRE). 
 
 
The provirus stays integrated in the host DNA during periods of time of variable length. At some 
point, mRNA is transcribed from the viral DNA, and once in the cytoplasm it is translated into the 
specific proteins of the virus. These proteins, along with viral RNA transcribed from the DNA, 
assemble to form new viral particles that are released from the cell budding from the plasma 
membrane. 
 
1.1. Long Terminal Repeats (LTR) 
 
The RNA genome of retroviral particles is flanked by two short repeated sequences (R), associated 
to the regions U5 and U3 in the 5’and 3’ends, respectively. U5 and U3 are duplicated during the 
reverse transcription of the RNA genome into dsDNA, providing the provirus with a new terminal 
sequence U3-R-U5 flanking each end, which binds covalently to the host DNA (Figure 1). These new 
sequences are termed Long Terminal Repeats (LTRs); their size ranges between 300 and 1200 bp, 
depending on the retrovirus, and they are the control centers for gene expression, containing all of the 
requisite signals for this function: enhancers, promoters, transcription initiation (capping), transcription 
terminator and polyadenylation signal.  Viruses 2009, 1                                       
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The transcription starts at the beginning of R, is capped and proceeds through U5 and the rest of the 
provirus, usually terminating by the addition of a poly A tract just after the R sequence in the 3’ LTR. 
The LTR contains two functional domains: a promoter region, and an enhancer region (Figure 1), 
which bind several protein factors (both general and tissue-specific). Enhancers are an important class 
of transcriptional regulatory elements, downstream from the transcription start site (i.e. cis-acting). 
Enhancers identified up-to-date show very little homology; they usually have a core domain, about 10-
15 bp long, that binds a specific cellular factor (such as hormones, mitogens, cytokines, nutrients or 
toxins), which regulates their expression [53, 111]. Most of these elements have a positive effect on 
transcription, but some do have a negative effect. The different members of these families vary 
significantly in their relative abundance, in their functional activity and in their interactions with other 
additional proteins, generating a complex transcriptional enhancers’ network, which is considered 
crucial [34, 75, 134, 139]. Thus, the LTR sequences of retroviruses in general, but especially of 
lentiviruses, offer various possibilities for regulation. This, along with the activity of the accessory 
regulatory proteins, allows the virus to alter specific biochemical routes of the cell, and enhance viral 
survival and its spread within the host, permitting them even to invade cellular environments not 
permissible to other viruses, such as cells which are not dividing. 
Some retroviruses contain additional enhancer sites, homologous to sequences detected in genes 
which are sensitive to the action of interferon (IFN), termed Interferon Stimulated Response Elements 
or ISREs (see below) (Figure 1). These sequences allow them to respond in a dose dependent manner 
to the presence of IFN, which thus directs transcription. 
The 3’ LTR is not normally functional as a promoter, although it has exactly the same sequence 
arrangement as the 5’ LTR. The function of the 3’ LTR is to act in transcription termination and 
polyadenylation. 
2. Interferon 
Interferons (IFNs) are a multigene family of inducible cytokines, which regulate immunity in 
infectious diseases and tumours [11, 17]. IFNs are commonly grouped into two types [107]. Type I 
IFNs (IFN-I), which possess antiviral activity and are associated with the innate immunity, are also 
known as viral IFNs and include amongst others IFN-α (leukocyte IFN), IFN-β (fibroblast IFN), IFN-
ω, and IFN-τ. Type II IFN (IFN-II), produced by activated T-cells and natural killer cells, is also 
known as immune IFN (IFN-γ) [16]. Type I IFNs induce antiproliferative and antiviral responses, and 
not only play an important role in the innate immune response, but also influence the generation of the 
adaptive immune responses [7, 52, 117].  
The induction of type I IFNs is regulated by two signal transduction pathways, both of which are 
activated by viruses [6, 56, 143]: the classical and the Toll-like receptors (TLR) pathways. 
Most cells, including fibroblasts, hepatocytes, and conventional dendritic cells, use the so-called 
classical pathway. These cells have cytosolic receptors (CR) [6] that are able to recognize viral nucleic 
acids within the infected cells. CR includes the RIG-I-like RNA helicase receptor (RLH) family: 
retinoic acid inducible gene-I (RIG-I) and melanoma differentiation associated gene 5 (MDA5) [138]. 
The presence of viral dsRNA activates the routes of NF-κB and Interferon Regulatory Factor (IRF)-3, 
the main regulatory factors for IFN transcription. NF-κB and IRF-3 translocate to the nucleus and bind Viruses 2009, 1                                       
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the promoter for the IFN-β gene, forming a complex named “enhanceasome”, which combines with 
other co-activators and RNA-polymerase, in order to transcribe IFN-β. Thus, cells secrete initially 
IFN-β. In the following amplification stage, IFN-β triggers the expression of IRF-7. This factor has 
been proposed as the main regulator of the expression of IFN-I genes [64], and, in collaboration with 
IRF-3, triggers the synthesis of IFN-α [56, 95] (Figure2). 
Figure 2. Simplified mechanism of regulation of the induction of the interferon genes in 
most cells. PKR, RNA dependent protein kinase; IRF, interferon regulatory factor; ISGF, 
IFN-stimulated gene factor; IFNAR, interferon alpha receptor; ISRE, interferon stimulated 
response elements. Ovals represent proteins, squares represent genes. 
 
 
Plasmacytoid dendritic cells (pDCs), also known as precursors of type 2 dendritic cells or natural 
IFN-producing cells, use the Toll-like receptors (TLR) pathway, expressed in the cell surface or in the 
endosomes, sensitive to viral DNA and RNA. The TLR signal activates IRF-7, which is constitutively 
expressed in these cells [50, 56, 58, 62, 65, 123], directly originating the secretion of high levels of 
IFN-α [31, 37, 49, 56] (Figure 3). 
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Figure 3. Simplified mechanism of regulation of the induction of the interferon genes in 
dendritic cells. IRF, interferon regulatory factor. Ovals represent proteins, squares 
represent genes. 
 
 
 
Once type I IFN is synthesized, it binds to the interferon alpha receptor (IFNAR), the specific 
receptor for IFN-I on the cell membrane, formed by two subunits: IFNAR-1 and IFNAR-2 (Figure 4). 
The binding of IFN-I to IFNAR-1 and 2 produces the heterodimerization of both subunits [10, 98, 
135], which activates the tyrosine kinases TYK-2 and JAK-1. This phosphorylates a related 
transcription factor which is in the cytoplasm, and which is involved in the signal transduction of 
several molecules, termed STAT (Signal Transduction and Activator of Transcription) [12, 85]. Of the 
several STAT proteins, IFN-α or -β phosphorylate STAT-1 and STAT-2, which bind p48 (IRF-9), 
forming a trimer (IFN-stimulated gene factor-3, ISGF-3). ISGF-3 translocates to the nucleus and binds 
the so-called Interferon-Stimulated Response Elements (ISRE) in IFN-inducible genes (ISGs). As 
mentioned before, ISREs are cis-acting DNA regulatory sequences; they have a consensus sequence 
a/gNGAAANNGAAACT [142,146], very similar to the IRF elements (IRF-E, whose consensus 
sequence G(A)AAAg/ct/cGAAAg/ct/c is present within the promoters of IFN-I and of most ISGs) [96] 
(Figure 4). Antiviral activities associated with IFN-α include, among others, the induction of protein 
Mx GTPase, activation of protein kinase R (PKR) leading to mRNA translation, and activation of the 
2’,5’-OAS/RNase L system, resulting in RNA degradation [54, 119]. 
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Figure 4. Induction mechanism of genes by type I interferons. IFNAR, IFN-α receptor; 
IRF, interferon regulatory factor; ISGF, IFN-stimulated gene factor; ISRE, interferon-
stimulated response element; TYK, tyrosine kinase; JAK, Janus kinase; STAT, Signal 
Transduction and Activator of Transcription. 
 
 
IFN-I plays an important role in the defense against viral infections, both through IFN-induced 
proteins and enzymes mentioned above (innate response), as well as through its effect on the adaptive 
immune response, since the maturation of dendritic cells by IFN is important for the stimulation of T-
cells [52, 117]. In addition, type I IFNs increase the expression of class I MHC molecules in all cells, 
contributing to the removal of the infected cells [7]. In HIV infections, results are controversial; some 
researchers have proposed that the effect of IFN may be beneficial, while other deleterious, since it 
may activate apoptosis of CD4+ T-cells, both non-infected and HIV-infected, through the expression 
of TNF-related apoptosis inducing ligand (TRAIL) and death receptor (DR) 5 in their membrane [60].  
When IFN-I is administered to HIV-, simian immunodeficiency virus (SIV)-, or feline 
immunodeficiency virus (FIV)-infected individuals clinical signs are seen to improve [30, 33, 60, 106, 
117], supporting the hypothesis that type I IFNs play important roles in the response to these 
retroviruses, as well as to other retroviruses, such as HTLV-I [46, 79, 117], BLV [78], feline leukemia 
virus (FeLV) [28, 149], or MuLV [2, 52]. 
These effects of IFN-I may be observed both in vivo and in vitro. In the following paragraphs 
evidence will be discussed on the observations on  
-  IFN-I levels in natural and experimental retroviral infection, and whether they are protective or 
deleterious, and association to specific syndromes, such as dementia 
-  Possible impairment of pDCs as the cause of altered IFN levels Viruses 2009, 1                                       
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-  Effects of IFN on virogenesis  
-  Effects of IFN at the cellular level: induction of apoptosis in infected and non infected cells 
-  Effects of IFN at the molecular level: presence of ISREs in retroviral genome (LTRs) 
-  Mechanisms by which retroviruses may evade the effect of IFN-I 
Most data originate from studies performed with IFN-α. However, due to their similarity, in the next 
sections either IFN-α or IFN-β are referred to as IFN-I. In the last section, some results obtained with 
other type I IFNs are reviewed. 
3. Evidence of the Importance in Vivo of Type I Interferons in Retroviral Infections  
3.1. Systemic IFN levels and their relationship with pathogenesis 
Most of the data regarding the relevance of IFN-I on retroviruses stem from results on the infection 
with HIV. Several data suggest that in vivo IFN-α production may play an important role in the 
pathogenesis of HIV-1 infection. However, the effect of IFN is difficult to establish, as many factors 
may be involved in the implacable immune system activation and dysfunction underlying AIDS 
progression. Alterations in the production levels of IFN-I were among the earliest reported laboratory 
abnormalities in AIDS patients, with descriptions of elevated serum levels of an unusual acid-labile 
IFN-α in patients with Kaposi’s sarcoma and hemophilia [43].  
During early infection steps in HIV-infected persons IFN-α production has been reported to be 
decreased. This process is accompanied by a decrease in the CD4+ T-cell population, and may be used 
as an additional marker permitting to determine the HIV stage. Contrariwise, higher concentrations of 
serum IFN-α have been detected in patients with more advanced HIV infection [116, 141] and have 
been found to correlate with p24 antigenemia [140]. In disagreement with these data it has been 
reported that asymptomatic non-progressors naturally infected by HIV have augmented levels of IFN-α 
[132] which correlate with higher levels of CD4+ T-cells, low HIV load and absence of opportunistic 
infections [44, 47, 132]. In these cases, high levels of IFN-α may play a protective role in HIV/AIDS 
progression. Similar findings have been reported for HTLV-I and Friend murine leukemia virus (F-
MuLV) infections. Viral expression in HTLV-I-infected cells is significantly suppressed when the 
infected cells are intraperitoneally injected into wild-type mice, but not when they are inoculated into 
interferon regulatory factor (IRF)-7 knockout mice that are deficient of type-I interferon responses 
[79]. In mice infected with and treated early during infection with IFN-I, viral loads in spleen and 
plasma were significantly lower than in untreated mice [52], suggesting that IFN is able to control both 
HTLV and F-MuLV infections.  
The decreased efficacy of IFN with time in controlling retroviral infection may be due to several 
factors, being one of them the development of IFN-resistant retrovirus clones. Studies on sensitivity to 
IFN-I have shown that primary HIV isolates derived from patients at various stages of HIV infection 
displayed a broad range of sensitivity to IFN-α2. The prevalence of IFN-α2 resistance is low in isolates 
from asymptomatic patients but increases notably once HIV infection progressed to AIDS, when 
serum levels of IFN-α are higher, and thus it appears that IFN-α either promotes resistance, or favors 
survival of IFN-α resistant variants [74, 83]. The pathogenesis staging proposed has been that IFN-I 
synthesis is normal during HIV infection stages I and II, stages when HIV infection is inhibited. Viruses 2009, 1                                       
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However, during the persistent HIV infection, the CD4+ T-cells numbers drop drastically, concurrently 
with local IFN production. These events are usually followed by infection acceleration, antigenemia 
and viremia, as well as opportunistic infections which cause the increased and prolonged IFN-I 
synthesis, which, in turn, leads to IFN tolerance and resistance [74, 81]. 
In addition, it has been reported that IFN may increase the expression of MHC type I molecules in 
most T-cells [76], which may originate the selection of CD8+ T-cells [77]. This sustains the hypothesis 
that high concentrations of IFN-α may be deleterious through the stimulation of cytokine production; 
activation of pDCs by HIV stimulates IFN-I secretion, which contributes to T-cell activation. T-cells 
thus activated show reduced proliferation after TCR stimulation [18]. T-cells have also been reported 
to be affected in HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) IFN-treated 
patients; the frequency of perforin expression in CD8+ T-cells was significantly decreased after 
treatment in HTLV-infected patients who experienced clinical improvement, while it was increased in 
patients who did not experience such an improvement [117]. Thus, the role of type I IFN on retroviral 
pathogenesis (whether it is protective or harmful) is still unclear. 
In SIV the mechanism seems to be similar to HIV, though some differences have been observed. 
SIV infection may be very virulent/pathogenic for certain species, such as rhesus macaques (Macaca 
mulatta), while for others, which constitute the natural reservoir for SIV, such as sooty mangabeys 
(Cercocebus atys), the clinical outcome does not progress to AIDS and maintain healthy populations of 
CD4+ T-cells, despite high viral loads [90]. It has been shown that sooty mangabeys have substantially 
reduced levels of innate immune system activation in vivo during acute and chronic SIV infection and 
their pDCs produce markedly less IFN-α in response to SIV and other TLR7 and 9 ligands ex vivo [38, 
90, 140]. Thus, the chronic stimulation of pDCs by retroviruses in non-natural hosts may overactivate 
the immune system and induce the dysfunction underlying AIDS progression, a phenomenon that does 
not happen in sooty mangabeys, the natural hosts [90, 140]. 
The low level of T-cell activation in African Green Monkey (Cercopithecus aethiops), which is 
associated with protection against AIDS in nonpathogenic SIVagm infection, may be partly due also to 
the lack of inflammatory cytokine responses which happens in this species. In SIVagm, bioactive IFN-
α was detected in plasma concomitant with the peak of viremia, unlike IL-6 and IL-12 [38]. Thus, in 
the nonpathogenic SIVagm model, the low level of inflammatory cytokines may be responsible for the 
low level of T-cell activation, associated with protection against AIDS [38]. 
In summary, it appears that type I IFN is effective in controlling the in vivo infection by 
retroviruses, though its continual presence may also over-stimulate the immune system to the point 
where it might be deleterious, both by activating cellular function and apoptosis (see below), and by 
selecting IFN-resistant clones.  
3.2. Local IFN levels and their association with dementia  
A possible outcome of the infection by some retroviruses is the central nervous system (CNS) 
involvement, with the development of different degree of dementia. It has been observed that IFN-α 
levels are increased in the cerebrospinal fluid (CSF) of HIV associated dementia, suggesting that this 
cytokine may play a role in the pathogenesis of this disease [113, 121]. In a model using mice 
inoculated intracerebrally with HIV-infected macrophages it was seen that increased levels of IFN-α in Viruses 2009, 1                                       
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the brain correlated directly with cognitive deficits [120]. HIV encephalitis developed in these mice, 
and blocking IFN-α with neutralizing antibodies significantly improved cognitive function, decreased 
microgliosis and prevented loss of dendritic arborization in the brains. This effect is also observed in 
vitro [123]. Similar observations correspond to SIV infection, as early antiretroviral treatment is seen 
to lower brain levels of IFN-α and prevent CNS dysfunction by decreasing brain viral load [94]. Some 
data suggest that HIV-1 activates pro-inflammatory and IFN-α-inducible genes in human brain 
endothelial cells and that these genes are linked to the JAK/STAT pathway. According to these data, 
STAT1 activation plays a crucial role in HIV-1-induced brain damage and in neuropathogenesis [23]. 
3.3. pDCs impairment 
An important role of type I IFN in the innate response to HIV-1 infection is suggested by the 
observation that deletion of pDCs results in rapid progression of HIV-1 infection in vivo [86]. In acute 
and chronic HIV-1 infection, pDC counts [5, 25, 39, 44, 47, 73, 104, 122, 132, 133] and function [5, 
14, 25, 40, 44, 47, 73, 133] are severely reduced, reflecting the clinical status of the infected patients 
and predicting immunological control of HIV-1 replication [105]. Except for the development of 
dementia, it appears that high levels of IFN-α are beneficial (at least initially, till the immune system 
gets over-stimulated) and suppress the advancement of symptoms in HIV patients. High HIV proviral 
loads usually correlate with loss of circulating pDCs, the cell type mostly responsible for the 
production of IFN-I in response to viruses, and occurrence of opportunistic infections [133]. 
Why do pDCs counts decrease during some retroviral infections? The decrease of pDCs in blood 
may not represent an absolute loss of these cells, but rather that they are recruited to specific tissues. 
To this regard, pDCs are seen to accumulate in the spleen in some HIV-positive patients or migrate to 
lymphoid tissues [62], possibly driven by p17(MA). This viral protein has been seen to induce 
immature circulating pDCs to home in lymph nodes, devoid of their ability to serve as a link between 
innate and adaptive immune systems [48]. 
A similar phenomenon (declines of blood pDCs numbers but increased presence of these cells in 
lymph node during acute infection) is also observed in SIVagm infection [38]. pDCs recruited to the 
lymph nodes display increased, but transient IFN-α production,  
pDCs isolated from HIV-1 infected patients demonstrate functional abnormalities, including 
diminished production of IFN-α when exposed to viruses in vitro [87, 141]. Why are pDCs impaired? 
It has been shown that HIV can directly infect pDCs in vitro, providing a potential explanation for 
their  in vivo depletion [133, 148]. Synthetic viral Vpr, a weak transcriptional activator of HIV, 
substantially inhibits IFN-I production by pDCs without inducing their apoptosis [66], supporting the 
hypothesis that some HIV proteins may affect IFN production by pDCs. In fact, pDCs do not even 
need to be infected by HIV to show altered IFN production, but are elicited by interactions with HIV-1 
virions or certain viral components [148], and the attachment of HIV-1 to pDCs by CD4 through 
gp120(SU) is critical for subsequent IFN-α production [59]. Nevertheless, diminished production of 
IFN-I in vitro by pDCs from HIV-1 infected patients may not represent diminished IFN production in 
vivo. Thus, the elevations in serum IFN-α levels observed in patients with early infection and advanced 
HIV disease [141], despite the diminished in vitro ability of pDCs to produce IFN-α following 
stimulation described above have been explained in the sense that IFN-I or even HIV virions may have Viruses 2009, 1                                       
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activated pDCs previously, hindering their IFN-I production when they are later stimulated in vitro 
[141]. 
In other retrovirus such as HTLV-I, infection of pDCs resulted in impaired IFN-α production and 
correlated with elevated HTLV-I proviral load in infected individuals [63]. 
4. Effects of Interferon on Retroviral Virogenesis 
The in vitro effects of IFN-I on retroviruses have been extensively studied. Though most results 
suggest that IFN affects the latter stages of the viral cycle, important discrepancies are observed. These 
may be due to different factors, such as whether cell lines (lymphoblastoid vs monocytic) or primary 
cultures (PBMC, monocyte/macrophage lineage, or CD4+ T-cells) are studied, or whether it is an acute 
or chronic cellular infection. The degree of in vitro inhibition may be due to the virus isolate, the target 
cell, the concentration of IFN, the multiplicity of infection, and the time of infection or of treatment. 
Most studies seem to indicate that the effects of IFN-I are more evident when cells are pretreated 
with this cytokine before viral infection. In studies with HIV, the inhibitory effect of IFN has been 
observed even when it was added at the moment of infection, since cells (monocytes or T-cells) treated 
with IFN at the time of virus challenge showed no p24 antigen or RT activity, no HIV-specific mRNA, 
and no proviral DNA [4, 51, 81, 97, 108, 127]. Contrariwise, it was shown that crude human IFN-α 
(HuIFN-α) inhibits the replication of FeLV (as evidenced by the titration of the infectious progeny) in 
feline cell cultures more markedly when it was added within one day after the inoculation of the cells 
rather than when it was applied before cell infection [69]. In any case, most of the studies have been 
done treating cells with IFN after retroviral infection. 
Parameters studied have been mostly viral protein synthesis and infectivity, though proviral 
integration has commonly also been determined. Viral protein synthesis is measured either by 
evaluating the mRNAs or directly measuring the amount of specific proteins. In some retroviruses, 
such as FeLV, capsid protein is used to detect viremia in infected individuals. It is produced in excess 
by infected cells, and it may be secreted into the extracellular environment not bound to infectious 
particles [70]. Infectivity is generally estimated through RT activity in the supernatant of treated 
infected cells [101], as infective viral particles must carry RT [28]. Infectivity can be also evaluated 
through syncytia formation [71, 102]. 
The infectivity of viral particles in IFN-treated cell supernatants was shown to be slightly [51, 131] 
to drastically [28, 57, 36, 89, 102] reduced. Most studies have shown that protein synthesis is not 
affected by IFN-I. HIV p24 antigen levels have been reported to remain unaltered in the supernatant 
after treating infected cells with IFN-I [27, 51, 131]. Other results with HIV showed that the cell-
associated fraction of p24(CA) was dose-dependently enhanced by IFN, while the shed fraction of this 
protein was unmodified [36], and levels of p24(CA) antigen and RT activity in lysates of IFN-treated 
infected cells were threefold greater than those of controls. In the case of FeLV [28, 147] and FIV [29], 
levels of capsid proteins in the supernatant of infected cells were not affected by IFN treatment, while 
RT activity decreased in a dose-dependent manner. These results seem to suggest that IFN interrupts 
the last stages of the virogenesis, avoiding the correct assembly and the release of viral particles; 
electron microscopy results support this hypothesis, as it showed that aberrant particles were formed in 
IFN-treated HIV-infected cells [36]. Viruses 2009, 1                                       
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The effect on protein synthesis may be selective. In the case of HTLV-I, where virus transmission 
and production were strongly suppressed in the presence of IFN-α or IFN-β, the expression of certain 
virus specific proteins, such as gp46(SU) (but not p19(MA), p24(CA), p28, p36 and gp68) was 
affected by IFNs [55, 102], a phenomenon that was not observed by other researchers [46]. 
Electron microscope reveals that some of the HTLV-I particles in cells treated with high doses of 
IFN-I are trapped in the intracellular vacuoles [102]. Similar results were observed with some murine 
retroviruses (Moloney murine leukemia virus, MoMLV), which exhibited altered release of virus when 
cells were treated with IFN-α, resulting in the accumulation of intracellular virions in cytoplasmic 
vacuoles [3, 131]. Extracellular RT activity and p24 levels decreased in parallel with increasing IFN, 
whereas the intracellular viral proteins decreased only slightly [131]. Virions released from these cells 
contained typical viral RNA, proteins and glycoproteins, as determined by gel-electrophoresis [3, 131]. 
However, radioimmunoprecipitation analyses of IFN-treated HIV T-cell lysates show that, although 
viral proteins accumulate in intracellular compartments, they fail to form viral particles. Taken 
together, the results mentioned above suggest that type I IFNs do not inhibit HIV, HTLV, FeLV, FIV 
or MoMLV gene expression strikingly, but suppress processing or assembly of virus proteins and/or 
release of virions in the late phase of maturation. 
The mechanism by which IFN may inhibit the assembly and/or release of mature viral particles has 
also been intensely studied. According to some studies, HIV viral particles from IFN-treated cultures 
contained a significant lower quantity of the specific gp120(SU), and a decreased ability to bind with 
their target CD4+ T-cells; gp120(SU) accumulated in aberrant cell compartments, and exhibited 
altered folding. Thus the diminished infectivity of newly formed particles could be due to defective 
virion formation [36, 57]. Similar results had been obtained previously for MoMLV, where it was 
shown that IFN exerted a significant inhibitory effect on the glycosylation of the Env proteins, which 
may lead to the production of defective noninfectious virions [2]. 
However, most recent observations suggest that IFN may affect virogenesis by inducing changes on 
the gag gene products [45, 46, 103]. It has been reported that IFN-I may produce a change in post-
translation modifications of Gag proteins, as more basic forms of p55, p39 and p24 were detected in 
HIV-infected stable cell lines, which inhibit capsid polyprotein processing. In addition, particles 
remaining attached to the cell failed to mature into structures with condensed cores [8]. Other studies 
suggest that IFN-α blocks HIV-I release mediated by the ubiquitin ligase, ISG-15, one the IFN-induced 
proteins of the ubiquitin-like pathway. This inhibition occurs by altering protein interaction and 
ubiquitination steps of Gag required for virus release, without having any effect on the synthesis of 
HIV-1 proteins in the cell, although the precise mechanism is still unclear [103]. 
The proper assembly and budding of retrovirus particles are dependent on the interaction of viral 
Gag polyprotein with lipid rafts at the plasma membrane. Lipid rafts are the dynamic assemblies of 
selected proteins, cholesterol and sphingolipids that exist in the exoplasmic part of cellular bilayer 
membranes [21, 88]. Studies with HTLV-I show that IFN-α prevents Gag proteins from associating 
with the lipid rafts, affecting assembly and thus blocking viral replication [46]. It is not clear whether 
this alteration is due to the modification of the lipid or proteic composition of the rafts, to its action on 
the chaperones, to the disturbance of the lipid raft environment critical for IFN-I signaling to STAT 
proteins, or to post-translational modification of the Gag proteins [45, 46, 93]. Viruses 2009, 1                                       
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Though there is compelling evidence that type I IFNs affect the terminal stages of the retroviral 
cycle, other studies seem to prove that IFN may inhibit the early phases of replication, decreasing virus 
uptake and entry, DNA synthesis by RT, the levels of integrated provirus and of RNA and proteins 
expressed [9, 36, 126, 127]. These discrepancies may be due to the retrovirus infection status of the 
cell; in de novo infections (i.e. cells which are infected for the experiment), the effect of IFN-I may be 
in the early stages of the cycle, while in the chronic infections (primary cells or cell lines already 
infected), IFN may inhibit replication in the later stages [36, 126]. It was reported that IFN-α inhibited 
effectively the first HIV-1 replication cycle by decreasing the relative RNA and protein levels in cells. 
The levels of integrated proviral DNA were significantly lower in IFN-α treated cells compared to 
non-treated controls, suggesting that the effect of IFN-α was at the level of proviral DNA formation or 
integration [127]. 
The discrepancies might be associated also to specific retroviruses [126]. To this respect, viral 
specific mRNAs have been shown to decrease markedly in SIV-infected IFN-treated cells, but not in 
HIV-1-infected cells. It was concluded that IFN inhibited an earlier stage of replication in SIV-infected 
cells, in a step between attachment and reverse transcription [137]. 
Several mechanisms involving genes induced by IFN have also been proposed. The expression of 
the genes encoding for Mx and OAS induced by IFN-I has been reported to inhibit the formation of 
viral particles and to reduce HIV-1 RT activity [9, 126] and p24 synthesis [131].  
Over the past few years some intracellular proteins with antiretroviral activities, referred as 
restriction factors, have been described in several infected host cells. Examples of these molecules are 
APOBEC3G/F and TRIMs families. APOBEC3G/F are cytidine deaminases that are able to strongly 
inhibit retroviral replication and that are neutralized by lentiviral Vif protein. TRIM5α may block 
reverse transcription by rapidly recruiting TRIM5α-associated virus to the proteosome and degrading it 
(reviewed in 67, 84], although very often TRIM from a particular mammalian species does not restrict 
infections by retroviruses of the same mammalian species. Both antiretroviral factors, APOBEC3G/F 
and TRIMs, are upregulated by IFN-α in infected cells, resulting in enhanced antiviral activity against 
HIV-2, SIVmac, or N-tropic MuLV infection. Moreover, high expression levels of TRIM5α play an 
essential role in controlling both the initial retroviral exposure and the subsequent viral dissemination 
in vivo [118]. Recently, the ability of TRIMs to block retroviral replication in the late stages of viral 
particle production has been described in HIV-1 infected cells, which appears to account for some of 
the interferon´s antiviral activity against HIV-1 budding [67]. 
5. Effects of IFN at the Cellular Level: Apoptosis  
In the preceding section, it has been discussed that type I IFNs inhibit the final release of retrovirus 
particles from the cells, resulting in an accumulation of cell-associated virions, or producing defective 
noninfectious virus particles, apparently due to the interference with the processing of viral proteins 
and their assembly into complete virions, without altering significantly retroviral protein synthesis. 
This prompted researchers to hypothesize that these effects of IFN-I are a result of a cellular 
interaction with IFN rather than a result of the antiviral activity of IFN [32]. 
One of the effects of IFN on the cell is the induction of apoptosis. Apoptosis plays a critical role in 
cellular differentiation, in the elimination of cells that sustain genetic damage or undergo uncontrolled Viruses 2009, 1                                       
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cellular proliferation, and in preventing viral replication by eliminating virus-infected cells [24]. The 
potential of IFN to induce apoptosis has been known for some time. In general, the prolonged activity 
of IFN-induced proteins leads to cell death by apoptosis, a response that certainly limits spread of virus 
from one cell to another. IFN activates the expression of genes which contribute to apoptosis. For 
example, STAT1, which is critical for signaling for both types of IFN, has been proposed to play a role 
also in apoptosis. PKR molecules regulate the expression of genes involved in apoptosis, possibly 
involving signaling through the NF-κB pathway [13]. Though IFNs are positive mediators of cell 
death, there are instances where both type-I and –II IFNs may actually prevent apoptosis [13]. 
Strong and sustained induction of TRAIL and/or Fas/FasL in response to IFN has been shown to 
lead to recruitment and activation of the Fas associated death domain (FADD). FADD plays an 
important role in IFN mediated apoptosis as transfection experiments, using dominant negative 
mutants of FADD, conferred IFN-resistance to sensitive cells. FADD activation, in turn, activates 
caspase-8, initiating activation of the caspase cascade. Activated caspase-8 cleaves Bid, a proapoptotic 
member of Bcl2 family, resulting in disruption of mitochondrial potential, release of cytochome c from 
the mitochondria into the cytoplasm, where it acts as a cofactor to stimulate the complexing of Apaf1 
with caspase-9. This complex potentiates caspase-3 activation, followed by changes in plasma 
membrane symmetry, cleavage of PARP, chromatin condensation and DNA fragmentation and cell 
death [24]. 
It was long envisioned that the effect of IFN on retroviruses could be a consequence of its 
interaction with the cell membrane. Thus, apoptosis induction and the existence of lipid rafts were 
predicted [2]. Using selective stains, type I IFNs have been shown to induce apoptosis in FeLV- and 
FIV-infected cells, to a degree several orders of magnitude higher than in non-treated cells [28, 29]. It 
was concluded that the intracellular and/or the slight changes in the cell membrane derived from the 
synergic action of viral infection and IFN-I could lead to a reduced release of viral particles (evaluated 
indirectly by the RT activity). This would limit the spread of the infection to other cells, and originate 
the selective death of infective cells [28]. 
The effects of apoptosis induced by IFN are not limited to retrovirus-infected cells. More notably 
apoptosis stimulated by IFN-I has been proposed as a mechanism to explain non-infected bystander 
CD4+ T-cells depletion and disease progression in HIV infection [1, 60, 61, 68, 92, 96]: in vitro, HIV-
1 gp120(SU) in the membrane of infected CD4+ T-cells stimulates the production of IFN in dendritic 
cells, which induces the expression of TRAIL by infected and non-infected CD4+ T-cells [61]. 
According to this model, in progressing individuals with high plasma viral loads, HIV binds to CD4 on 
pDCs, resulting in their activation, IFN-α production and migration from blood to lymphoid tissues. 
IFN-α binds to its receptor on infected and non infected CD4+ T-cells (resulting in STAT-1/2 
regulated expression of membrane TRAIL), and HIV gp120(SU) binds to CD4 on these cells. This 
latter event is required for the expression of the TRAIL death receptor 5 (DR5). Given that a high 
percentage of viral particles are not infective, but they still carry gp120(SU), DR5 is expressed on 
many non-infected CD4+ T-cells. TRAIL binds to DR5, resulting in CD4+ T-cell apoptosis. 
Contrariwise, in non progressing patients with very low plasma viral loads, pDCs do not produce IFN-
α and the expression of TRAIL is not induced, and the previous cascade, resulting in apoptosis, is not 
initiated [60]. According to another hypothesis, the viral protein Nef, a virulence factor that plays 
multiple roles in HIV replication, is capable of inducing proapoptotic effects in uninfected bystander Viruses 2009, 1                                       
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cells, and antiapoptotic effects in infected cells. Nef activates the synthesis and secretion of a set of 
chemokines/cytokines that activate STAT1 and STAT3, as well as IRF-3, leading to the synthesis of 
IFN-β, which, in turn, induces STAT2 phosphorylation [92].  
This cytotoxic mechanism and the stimulation of NK cells [145] may be responsible for the high 
degree of apoptosis observed in non-infected CD4+ T-cells in HIV-1 infected patients [42]. Other 
mechanisms involve the upregulation by HIV-1 of the gene expression of p53, associated with HIV-
mediated IFN-I synthesis [68], or the induction of IRF-1 by HIV-1, as this factor is clearly involved in 
apoptosis of activated T-cells and in the context of the machinery that T- cells use to induce apoptosis 
in their target cells [96]. 
6. Direct Effects of Type I Interferons at the Molecular Level: ISREs 
As mentioned previously, ISREs are DNA sequences which bind with the well-conserved N-
terminal region of the interferon regulatory factors (IRFs). By this mechanism, IRFs regulate the 
expression of genes stimulated by IFN, activating or either repressing gene transcription, depending on 
the target gene. IRFs are involved in multiple biological processes including regulation of immune 
responses and host defense, cytokine signaling, cell growth regulation and hematopoietic development. 
ISREs are present on the promoters of the target genes, i.e. the IFN-α or IFN-β genes and some IFN-
stimulated genes (ISG) (for a review of different ISRE sequences, see 142]. Sequences homologous to 
the ISREs have been identified in several retroviruses. For example, in HIV a sequence 
(TTGAAAGCGAAAGGGAAACC) homologous to ISRE has been identified in the 5’ HIV-1 LTR 
downstream of the HIV-1 transcription start site (Figure 1). This sequence is a binding site for several 
IRFs and its deletion results in impaired LTR promoter activity and altered synthesis of viral RNA and 
proteins [15]. In vivo it recruits IRF-1 and IRF-3 [144]. Other researchers have reported that it has a 
binding site for IRF-1 and IRF-2 [15, 96], but only IRF-1 is able to stimulate HIV-LTR transcription 
(and reactivates provirus from latency), interacts with Tat [124], and increases HIV-1 replication [96,  
125]. HIV is able to induce IRF-1 early upon infection, before the expression of Tat, and it is possible 
that it plays an important role in the early phases of HIV infection and as a strategy to counteract IFN-
mediated host defenses [124, review in 125] On the other hand, IRF-8 represses IRF-1-Tat-mediated 
transactivation of the LTR by interfering with IRF-1-Tat association, and it inhibits HIV-1 replication 
in CD4+ cells [96, 99]. 
In FeLV the sequence GGTTTCATTTTCG, matching the consensus NAGTTTCNNTTTCNC/T 
[146], was found at nucleotide 798, in a region just upstream from that which encodes the Gag-Pol 
precursor polyprotein gPr80; however, as it is not in the LTR regulatory region, it is difficult to link it 
with the initiation of transcription of the viral genome [28]. 
The region situated immediately downstream from the transcription start site (U5) in the BLV LTR 
is involved in regulation of viral gene expression. It contains a positive regulatory element in its 5’ 
region (nt +230 to +275) that functions either at the transcriptional or past-transcriptional level. This 
U5 region contains a sequence (nt +251 to +261) highly similar to an ISRE 
(TACTTTCTGTTTCTCG), which binds IRF-1 and IRF-2, but not ISGF3, and thus can be considered 
an IRF binding site, rather than a classical ISRE. Its failure to confer IFN responsiveness is most Viruses 2009, 1                                       
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probably due to its inability to bind ISGF3. This motif is required for optimal basal gene expression 
from the BLV LTR [78]. 
Up till now, no ISRE sequences have been identified in HTLV, FIV or other retroviruses, despite 
the effects of IFN on these viruses, which suggests that the molecular mechanisms involved may be 
more complex than anticipated and are still to be clarified. 
7. Mechanisms by which Retroviruses May Evade the Effects of Type I Inteferons 
Viruses have evolved different mechanisms that allow them to evade the antiviral response induced 
by IFN. This anti-IFN activity may be produced at three distinct time points: during IFN synthesis, 
during signaling, and through the alteration of the antiviral proteins induced by IFN. Some viral 
proteins are suppressors of IFN gene expression through their general inhibitory effect on host gene 
transcription [56]. However, they can also evade specifically the action of IFN. The major strategies 
include [45, 112] (a) competition for binding to IFN receptors; (b) inhibition of IFN production and 
secretion; (c) blockage of the signal of IFN; and (d) inhibition of the antiviral proteins induced by IFN 
or of their actions (Figure 5). 
Figure 5. Mechanisms by which viruses circumvent the effect of IFN. 1. Competition with 
IFN for receptors (IFNAR); 2. Inhibition of IFN synthesis and secretion; 3. Inhibition of 
the IFN signaling, which may happen at different levels; 4. Inhibition of the proteins 
stimulated by IFN, mostly of the PKR system. 
 
 
The mechanisms by which retroviruses evade IFN control belong to the fourth category. The 
presence of increasing levels of IFN in the serum of AIDS patients while viral replication continues 
and the disease progresses indicates that HIV-1 must employ a mechanism to evade the antiviral 
effects of IFN. However, the complexity of the virus-host interactions and the profound disregulation 
of the host cytokine network exerted by the virus at different stages during the infection have made 
these studies extremely difficult. In response to viral infection, IFN induces a number of genes 
including the dsRNA-dependent protein kinase R (PKR). PKR exerts its anti-viral activity by Viruses 2009, 1                                       
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phosphorylating the alpha subunit of eukaryotic translation initiation factor-2 (eIF-2), which results in 
the shut-down of protein synthesis in the cell. However, PKR activity is inhibited directly by HIV via 
the major regulatory protein, Tat [41]. This protein, in association with cellular factors, enhances the 
efficiency of transcription by cellular RNA polymerase 1000-fold, mainly by preventing premature 
termination of transcription. It triggers efficient RNA chain elongation by binding to TAR RNA, 
which forms the initial portion of the HIV-1 transcript. HIV-1 TAR is a highly-conserved stable RNA 
stem loop that interacts with Tat protein to regulate viral transcription [19]. HIV-1 Tat protein has been 
shown to act also as a substrate homologue of eIF-2, competing with it and preventing the 
phosphorylation of this factor, allowing protein synthesis and viral replication to proceed in the cell. 
Tat protein reduces the activity PKR significantly, while TAR RNA blocks its activation [41].  
Nef, a crucial determinant for HIV replication and pathogenesis, is believed also to play a major 
role in the evasion of the virus from the effect of IFN, by manipulating the phenotypical, 
morphological and functional characteristics of pDCs, rendering them incapable of activating CD8+ T-
cells and down-regulating their proliferation and functional competence [110]. 
The involvement of IRFs in HIV-1 replication allows to speculate that targeting IRFs (IRF-1, IRF-2 
and IRF-8) can be also regarded as a mechanism utilized by HIV-1 to evade the antiviral effect of IFN 
[96]. Other proteins of HIV degrade PKR and induce an inhibitor of RNaseL [96, 128]. 
HTLV blunts the expression of some genes induced by IFN, probably depressing the MxA, PKR 
and OAS pathways. Recently it has been described that HTLV-I did not have an effect either on the 
initiation of the IFN process (as it did not affect the cell surface presentation of IFNAR1 and IFNAR2 
or IFN-α binding). However, it reduced the phosphorylation of TYK2 and STAT2, and to a lesser 
extent, of JAK1 and STAT1, suggesting that the virus inhibits the IFN-induced specific activation of 
these cellular proteins [45]. Evidence that Gag and Pro may be responsible for this HTLV-I mediated 
IFN-α inhibition has also been provided [45]. These effects have also been ascribed to the viral protein 
Tax, a pleiotropic transcription factor that interferes with several of the cellular mechanisms and 
modulates transcription of a wide range of cellular genes [20]. It has been proposed that Tax protein of 
HTLV-I acts as an IFN-α antagonist, as it negatively modulates IFN-α induced JAK-STAT pathway by 
competing with STAT2 for coactivator CBP/p300, thereby inhibiting the transcription activation of 
STAT2-containing ISGF3 complex [150]. Tax may prevent by this mechanism IFN-α from exerting its 
antiviral, antiproliferative and proapoptototic effects, contributing to persistent viral infection and 
HTLV-I associated oncogenesis [150]. Nevertheless, it is possible that different HTLV-I gene 
products, other than Tax, may act at different levels of the IFN signaling pathways, coexisting more 
than one mechanism to evade IFN action, as has been shown for other viruses. 
8. Other Type I Interferons 
8.1. Interferon-tau (IFN-τ) 
IFN-τ is a noncytotoxic type I IFN responsible for maternal recognition of pregnancy in ruminants. 
It has been shown to have potent antiviral and antiproliferative activity. Data suggest that its anti-HIV 
activity is higher than IFN-α/β on primary PBMC and monocyte-derived macrophages infected in vitro 
by HIV [35]. Also, it induces IL-6 and IL-10 synthesis [91, 115]. The IFN-τ antiretroviral activity is Viruses 2009, 1                                       
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not associated with a decrease in either cell viability or immune reactivity [109], supporting the 
interest for the IFN-τ as an adjuvant therapy drug in HIV infection [26]. 
Like other IFNs, it seems to affect several steps of the HIV replication cycle. IFN-τ effectively 
inhibits the early steps of the biological cycle of HIV replication, particularly in human monocyte-
derived macrophages, decreasing intracellular HIV RNA and inhibiting the initiation of the reverse 
transcription of viral RNA into proviral DNA. Anti-HIV effects of IFN-τ are mediated by several 
modes of action, either directly by IFN-τ, or via other cytokines [91]. The mechanisms proposed are i) 
synthesis of cellular antiviral factors such as 2’,5’-OAS/RNase L and MxA protein [26], and ii) 
increased production of MIP-1α, MIP-1β, RANTES, natural ligands of CCR5, the principal coreceptor 
of HIV in macrophages [114]. 
The effects of IFN-τ have also been studied on BLV. BLV titers decreased in BLV-infected cells 
(FLK-BLV) and in peripheral blood mononuclear cells of BLV-infected cattle treated with 
recombinant bovine IFN-τ (rBoIFN-τ), demonstrating that this cytokine could directly inhibit BLV 
propagation rather than acting through its immunomodulatory effects [80]. 
Significant dose-dependent inhibition of reverse transcriptase activity by IFN-τ was detected by day 
6 of culture in FIV-infected feline PBL treated with IFN-τ. In addition, the production of the FIV core 
protein, p25(CA), was blocked. Both the amino- and carboxyl-terminal regions of IFN-τ, as identified 
by synthetic peptides, appeared to be involved in its antiretroviral activity. IFN-τ antiretroviral activity 
was not associated with a decrease in either cell viability or immunologic reactivity [109]. 
IFN-τ has an effect on the immune response of sheep. The immunomodulatory role of recombinant 
ovine IFN-τ (rOvIFN-τ) included the increase of the proportions of primary antiviral γδ
+and CD8+ 
immune cells in ovine lentivirus (SRLV)-infected lambs. This may represent a cellular mechanism to 
explain the antiviral and therapeutic efficacy of this cytokine, in addition to its direct antiviral effect 
[129]. The effect of rOvIFN-τ on the replication of SRLV in goat synovial membrane cells was studied 
by Juste et al. [71]. The strongest inhibitory effects were on syncytia formation and release of 
infectious virions into the cell culture supernatant, though the production of RT was not significantly 
different in cells treated with IFN-τ and in control cells. These results suggest that, as other type I 
IFNs, the action of this IFN is mostly on the latter steps of SRLV replication cycle, possibly by 
blocking virus assembly and/or release, thus limiting the spread of the infection [71]. In vivo results 
demonstrated a 90% reduction in SRLV titres in lambs infected experimentally with SRLV and that 
received early rOvIFN-τ treatment [72]. 
8.2. Interferon-omega (IFN-ω) 
IFN-ω is also a potent inhibitor of HIV replication in vitro; both laboratory and primary isolates of 
HIV-1 are more sensitive to IFN-ω than to IFN-α2, and protein synthesis is inhibited by IFN-ω to a 
greater degree than by IFN-α2. Data suggest that the expression of ISGs, particularly that of ISG-15, is 
higher and more sustained on treatment with the former than with the latter, which may confer a higher 
therapeutic index to IFN-ω in controlling HIV infection [82]. 
The in vitro effect of commercially available recombinant feline interferon omega (rFeIFN-ω) has 
been evaluated on the expression and replication of FeLV [28] and FIV [29, 136]. Very similarly to Viruses 2009, 1                                       
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IFN-α, rFeIFN-ω induced a marked inhibition of RT activity (and thus of infectivity), whereas it had 
no effect on protein synthesis. 
In summary, type I IFNs seem to play an important role in the innate immune response against 
retroviruses, but their effect is not well established. In vivo IFN-I levels vary throughout retroviral 
infections, though findings are contradictory, as for some researchers, high levels seem to be beneficial 
for the host to fight infection, while for others, they would provide a mechanism for deleting by 
apoptosis non-infected bystander cells. However, exogenous treatment with IFN-I appear to be 
generally valuable. In vitro findings support that type I IFNs undoubtedly inhibit replication of 
retroviruses, though there is not an unanimous agreement about whether it is at the early or late stages 
of virogenesis, and of whether it is by directly affecting the replication process or by altering cellular 
viability through apoptosis. Some retroviruses have ISRE-like sequences, which might modulate viral 
expression, and some are able to evade the effects of IFN, possibly through the regulatory proteins. 
References and Notes 
1.  Abbate, I.; Dianzani, F.; Capobianchi, M. R. Activation of signal transduction and apoptosis in 
healthy lymphomonocytes exposed to bystander HIV-1-infected cells. Clin. Exp. Immunol. 2000, 
122, 374-380. 
2.  Aboud, M.; Kimchi, R.; Bakhanashvili, M.; Salzberg, S. Intracellular production of virus 
particles and viral components in NIH/3T3 cells chronically infected with Moloney murine 
leukemia virus: effect of interferon. J. Virol. 1981, 40, 830-838. 
3.  Aboud, M.; Malik, Z.; Bari, S.; Kimchi, R.; Hassan, Y.; Salzberg, S. Effect of interferon on the 
formation and release of intracellular virions in NIH/3T3 cells chronically infected with Moloney 
murine leukemia virus. J. Interferon Res. 1983, 3, 33-44. 
4.  Agy, M.B.; Acker, R.L.; Sherbert, C.H.; Katze, M.G. Interferon treatment inhibits virus 
replication in HIV-1- and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for 
decreased stability and aberrant processing of HIV-1 proteins. Virology 1995, 214, 379-386. 
5.  Almeida, M.; Cordero, M.; Almeida, J.; Orfao, A. Different subsets of peripheral blood dendritic 
cells show distinct phenotypic and functional abnormalities in HIV-1 infection. AIDS 2005, 19, 
261–271. 
6.  Alsharifi, M.; Müllbacher, A.; Regner, M. Interferon type I responses in primary and secondary 
infections. Immunol. Cell. Biol. 2008, 86, 239-245. 
7.  Andrieu, M.; Chassin, D.; Desoutter, J.F.; Bouchaert, I.; Baillet, M.; Hanau, D.; Guillet, J.G.; 
Hosmalin, A. Downregulation of major histocompatibility class I on human dendritic cells by 
HIV Nef impairs antigen presentation to HIV-specific CD8+ T lymphocytes. AIDS Res. Hum. 
Retroviruses 2001, 17, 1365-1370. 
8.  Babé, L.M.; Unal, A.; Craik, C.S. Obstruction of HIV-1 particle release by interferon-α occurs 
before viral protease processing and is independent of envelope glycoprotein. J. Interferon 
Cytokine Res. 1997, 17, 287-93. 
9.  Baca-Regen L.; Heinzinger N.; Stevenson M.; Gendelman HE. Α interferon-induced 
antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production 
in human immunodeficiency virus type 1-infected monocytes. J. Virol. 1994, 68, 7559-7565. Viruses 2009, 1                                       
 
 
564
10.  Balachandran, S.; Kim, C.N.; Yeh, W.C.; Mak, T.W.; Bhalla, K.; Barber, G.N. Activation of the 
dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death 
signaling. EMBO J. 1998, 17, 6888-6902. 
11.  Baldwin, S.L.; Powell, T.D.; Sellins, K.S.; Radecki, S.V.; Cohen, J.J.; Milhausen, M.J. The 
biological effects of five feline IFN-α subtypes. Vet. Immunol. Immunopathol. 2004,  99,  
153-167. 
12.  Bandyopadhyay, SK.; Leonard, G.T. Jr.; Bandyopadhyay, T.; Stark, G.R.; Sen, G.C. 
Transcriptional induction by double-stranded RNA is mediated by interferon-stimulated response 
elements without activation of interferon-stimulated gene factor 3. J. Biol. Chem. 1995, 270, 
19624-9. 
13.  Barber, G.N. The interferons and cell death: guardians of the cell or accomplices of apoptosis? 
Semin. Cancer Biol.. 2000, 10, 103-111. 
14.  Barron, M.A.; Blyveis., N.; Palmer, B.E.; MaWhinney, S.; Wilson, C.C. Influence of plasma 
viremia on defects in number and immunophenotype of blood dendritic cell subsets in human 
immunodeficiency virus 1-infected individuals. J. Infect. Dis. 2003, 187, 26–37 
15.  Battistini, A.; Marsili, G.; Sgarbanti, M.; Ensoli, B.; Hiscott, J. IRF regulation of HIV-1 long 
terminal repeat activity. J. Interferon Cytokine Res. 2002, 22, 27-37. 
16.  Bekisz, J.; Schmeisser, H.; Hernandez, J.; Goldman, ND.; Zoon, KC. Human interferons α, beta 
and omega. Growth Factors 2004, 22, 243-251. 
17.  Belardelli, F.; Ferrantini, M.; Proietti, E.; Kirkwood, J.M. Interferon-α in tumor immunity and 
immunotherapy. Cytokine Growth Factor Rev. 2002, 13, 119-134. 
18.  Boasso, A.; Shearer, G.M. Chronic innate immune activation as a cause of HIV-1 
immunopathogenesis. Clin. Immunol. 2008, 126, 235-242. 
19.  Bolinger, C.; Boris-Lawrie, K. Mechanisms employed by retroviruses to exploit host factors for 
translational control of a complicated proteome. Retrovirology 2009, 6:8 (20 pp) 
20.  Boxus, M.; Twizere, J.C.; Legros, S.; Dewulf, J.F.; Kettmann, R.; Willems, L. The HTLV-1 Tax 
interactome. Retrovirology 2008, 5, 76. 
21.  Brown, D.A.; Rose, J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane 
subdomains during transport to the apical cell surface. Cell 1992, 68, 533-544. 
22.  Bushman, F.D. Targeting survival: integration site selection by retroviruses and LTR-
retrotransposons. Cell 2003, 115, 135-138. 
23.  Chaudhuri, A.; Yang, B.; Gendelman, H.E.; Persidsky, Y.; Kanmogne, G.D. STAT1 signaling 
modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the 
blood-brain barrier. Blood 2008, 111, 2062-2072. 
24.  Chawla-Sarkar, M.; Lindner, DJ.; Liu, Y.F.; Williams, B.R.; Sen, G.C.; Silverman, R.H.; 
Borden, E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of 
apoptosis. Apoptosis 2003, 8, 237-249. 
25.  Chehimi, J.; Campbell, D.E.; Azzoni, L.; Bacheller, D.; Papasavvas, E.; Jerandi, G.; Mounzer, 
K.; Kostman,J.; Trinchieri, G.; Montaner, L.J. Persistent decreases in blood plasmacytoid 
dendritic cell number and function despite effective highly active antiretroviral therapy and 
increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol.  2002,  168, 
4796–4801. Viruses 2009, 1                                       
 
 
565
26.  Clayette, P.; Martin, M.; Dereuddre-Bosquet, N.; Tournay, V.; Gras, G.; Martal, J.; Dormont, D. 
IFN-tau, a new interferon type I with antiretroviral activity. Pathol. Biol. (Paris) 1999, 47, 553-
559. 
27.  Coccia, E.M.; Krust, B.; Hovanessian, A.G. Specific inhibition of viral protein synthesis in HIV-
infected cells in response to interferon treatment. J. Biol. Chem. 1994, 269, 23087-23094. 
28.  Collado, V.M.; Gómez-Lucía, E.; Tejerizo, G.; Miró, G.; Escolar, E.; Martín, S.; Doménech, A. 
Effect of type I interferons on the expression of feline leukaemia virus. Vet. Microbiol. 2007, 
123, 180-186. 
29.  Collado, V.M.; Doménech, A.; Ballesteros, N.A.; Ramos, P.; Miró, G.; Gómez-Lucía, E. Efecto 
in vitro del interferón de tipo I en la expresión del virus de la inmunodeficiencia felina (FIV). In 
Proceedings of the Xth National Virology Congress, Salamanca, Spain, June 2009; p. 274. 
30.  Collado, unpublished results. 
31.  Colonna, M.; Krug, A.; Cella, M. Interferon-producing cells: on the front line in immune 
responses against pathogens. Curr. Opin. Immunol. 2002, 14, 373-379. 
32.  Czarniecki, C.W.; Sreevalsan, T.; Friedman, R.M.; Panet, A. Dissociation of interferon effects on 
murine leukemia virus and encephalomyocarditis virus replication in mouse cells. J. Virol. 1981, 
37, 827-831 
33.  de Mari, K.; Maynard, L.; Sanquer, A.; Lebreux, B.; Eun, H.M. Therapeutic effects of 
recombinant feline interferon-omega on feline leukemia virus (FeLV)-infected and FeLV/feline 
immunodeficiency virus (FIV)-coinfected symptomatic cats. J. Vet. Intern. Med. 2004, 18, 477-
478. 
34.  de Parseval, A; Elder, J.H. Demonstration that orf2 encodes the feline immunodeficiency virus 
transactivating (Tat) protein and characterization of a unique gene product with partial rev 
activity. J. Virol. 1999, 73, 608-617. 
35.  Dereuddre-Bosquet, N.; Clayette, P.; Martin, M.; Mabondzo, A.; Frétier, P.; Gras, G.; Martal, J.; 
Dormont, D. Anti-HIV potential of a new interferon, interferon-tau (trophoblastin). J. Acquir. 
ImmuneDefic. Syndr. Hum. Retrovirol.  1996, 11, 241-246. 
36.  Dianzani, F.; Castilletti, C.; Gentile, M.; Gelderblom, H.R.; Frezza, F.; Capobianchi, M.R. 
Effects of IFN α on late stages of HIV-1 replication cycle. Biochimie 1998, 80, 745-754. 
37.  Diebold, S.S.; Montoya, M.; Unger, H.; Alexopoulou, L.; Roy, P.; Haswell, L.E.; Al-Shamkhani, 
A.; Flavell, R.; Borrow, P.; Reis e Sousa, C. Viral infection switches non-plasmacytoid dendritic 
cells into high interferon producers. Nature 2003, 424, 324-328. 
38.  Diop, O.M.; Ploquin, M.J.; Mortara, L.; Faye, A.; Jacquelin, B.; Kunkel, D.; Lebon, P.; Butor, 
C.; Hosmalin, A.; Barré-Sinoussi, F.; Müller-Trutwin, M.C. Plasmacytoid dendritic cell 
dynamics and α interferon production during Simian immunodeficiency virus infection with a 
nonpathogenic outcome. J. Virol. 2008, 82, 5145-5152. 
39.  Donaghy, H.; Pozniak, A.; Gazzard, B.; Qazi, N.; Gilmour, J.; Gotch, F.; Patterson, S. Loss of 
blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 
infection correlates with HIV-1 RNA virus load. Blood 2001, 98, 2574–2576. 
40.  Donaghy, H.; Gazzard, B.; Gotch, F.; Patterson, S. Dysfunction and infection of freshly isolated 
blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003, 
101, 4505–4511. Viruses 2009, 1                                       
 
 
566
41.  Endo-Munoz, L.; Warby, T.; Harrich, D.; McMillan, NA. Phosphorylation of HIV Tat by PKR 
increases interaction with TAR RNA and enhances transcription. Virol. J. 2005, 2:17. Pp 13. 
42.  Estaquier, J.; Idziorek, T.; de Bels, F.; Barré-Sinoussi, F.; Hurtrel, B.; Aubertin, A.M.; Venet, A.; 
Mehtali, M.; Muchmore, E.; Michel, P.; Mouton, Y.; Girard, M.; Ameisen, J.C. Programmed cell 
death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate 
lentiviral infections. Proc. Natl. Acad. Sci. USA 1994, 91, 9431-9435. 
43.  Eyster, M.E.; Goedert, J.J.; Poon, M.C.; Preble, O.T. Acid-labile α interferon. A possible 
preclinical marker for the acquired immunodeficiency syndrome in hemophilia. N. Engl. J. Med. 
1983, 309, 583-586. 
44.  Feldman, S.; Stein, D.; Amrute, S.; Denny, T.; Garcia, Z.; Kloser, P.; Sun, Y.; Megjugorac, N.; 
Fitzgerald-Bocarsly, P. Decreased interferon-α production in HIV-infected patients correlates 
with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. Clin. 
Immunol. 2001, 101, 201–210. 
45.  Feng, X.; Ratner, L. Human T-cell leukemia virus type 1 blunts signaling by interferon α. 
Virology 2008, 374, 210-216. 
46.  Feng, X.; Heyden, N.V.; Ratner, L. Α interferon inhibits human T-cell leukemia virus type 1 
assembly by preventing Gag interaction with rafts. J. Virol. 2003, 77, 13389-13395. 
47.  Finke, J. S.; Shodell, M.; Shah, K.; Siegal, F. P.; Steinman, R.M. Dendritic cell numbers in the 
blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J. Clin. 
Immunol. 2004, 24, 647–652. 
48.  Fiorentini, S.; Riboldi, E.; Facchetti, F.; Avolio, M.; Fabbri, M.; Tosti, G.; Becker, PD.; Guzman, 
CA.; Sozzani, S.; Caruso, A. HIV-1 matrix protein p17 induces human plasmacytoid dendritic 
cells to acquire a migratory immature cell phenotype. Proc. Natl. Acad. Sci. USA 2008, 105, 
3867-3872. 
49.  Fitzgerald-Bocarsly, P.; Feng, D. The role of type I interferon production by dendritic cells in 
host defense. Biochimie 2007, 89, 843-855. 
50.  Gabriele, L.; Ozato, K. The role of the interferon regulatory factor (IRF) family in dendritic cell 
development and function. Cytokine Growth Factor Rev. 2007, 18, 503-510. 
51.  Gendelman, H.E.; Baca, L.M.; Turpin, J.; Kalter, D.C.; Hansen, B.; Orenstein, J.M.; 
Dieffenbach, C.W.; Friedman, R.M.; Meltzer, M.S. Regulation of HIV replication in infected 
monocytes by IFN-α. Mechanisms for viral restriction. J. Immunol. 1990, 145, 2669-2676. 
52.  Gerlach, N.; Schimmer, S.; Weiss, S.; Kalinke, U.; Dittmer, U. Effects of type I interferons on 
Friend retrovirus infection. J. Virol. 2006, 80, 3438-3444.  
53.  Gomez-Lucia, E.; Tejerizo, G.; Doménech, A. Effect of steroid hormones on retroviruses. In 
Oncogenic Viruses. Research Trends; Johannes, L.T.; Nova Biomedical: New York, USA, 2007; 
pp. 163-191. 
54.  Goodbourn, S.; Didcock, L.; Randall, R.E. Interferons: cell signalling, immune modulation, 
antiviral response and virus countermeasures. J. Gen. Virol. 2000, 81, 2341-2364. 
55.  Göttlinger, H.G.; Dorfman, T.; Sodroski, J.G.; Haseltine, W.A. Effect of mutations affecting the 
p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. USA 
1991, 88, 3195-3199. Viruses 2009, 1                                       
 
 
567
56.  Haller, O.; Kochs, G.; Weber, F. The interferon response circuit: induction and suppression by 
pathogenic viruses. Virology 2006, 344, 119-130. 
57.  Hansen, B.D.; Nara, P.L.; Maheshwari, R.K.; Sidhu, G.S.; Bernbaum, J.G.; Hoekzema, D.; 
Meltzer, M.S.; Gendelman, H.E. Loss of infectivity by progeny virus from α interferon-treated 
human immunodeficiency virus type 1-infected T cells is associated with defective assembly of 
envelope gp120. J. Virol. 1992, 66, 7543-7548. 
58.  Hardy, A.W.; Graham, D.R.; Shearer, G.M.; Herbeuval, J.P. HIV turns plasmacytoid dendritic 
cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like 
receptor 7-induced IFN-α. Proc. Natl. Acad. Sci. U S A. 2007, 104, 17453-17458. 
59.  Haupt, S.; Donhauser, N.; Chaipan, C.; Schuster, P.; Puffer, B.; Daniels, R.S.; Greenough, T.C.; 
Kirchhoff, F.; Schmidt, B. CD4 binding affinity determines human immunodeficiency virus type 
1-induced α interferon production in plasmacytoid dendritic cells. J. Virol. 2008, 82, 8900-8905. 
60.  Herbeuval, J.P.; Shearer, G.M. HIV-1 immunopathogenesis: how good interferon turns bad. Clin 
Immunol. 2007, 123, 121-128. 
61.  Herbeuval, J.P.; Grivel, J.C.; Boasso, A.; Hardy, A.W.; Chougnet, C.; Dolan, M.J.; Yagita, H.; 
Lifson, J.D.; Shearer, G.M. CD4+ T-cell death induced by infectious and noninfectious HIV-1: 
role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis.  Blood 2005, 106, 3524-
3531. 
62.  Herbeuval, J.P.; Nilsson, J.; Boasso, A.; Hardy, A.W.; Kruhlak, M.J.; Anderson, S.A.; Dolan, 
M.J.; Dy, M.; Andersson, J.; Shearer, G.M. Differential expression of IFN-α and TRAIL/DR5 in 
lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl. Acad. 
Sci. U S A. 2006, 103, 7000-7005. 
63.  Hishizawa, M.; Imada, K.; Kitawaki, T.; Ueda, M.; Kadowaki, N.; Uchiyama, T. Depletion and 
impaired interferon-α-producing capacity of blood plasmacytoid dendritic cells in human T-cell 
leukaemia virus type I-infected individuals. Br. J. Haematol. 2004, 125, 568-575. 
64.  Honda, K.; Yanai, H.; Negishi, H.; Asagiri, M.; Sato, M.; Mizutani, T.; Shimada, N.; Ohba, Y.; 
Takaoka, A.; Yoshida, N.; Taniguchi, T. IRF-7 is the master regulator of type-I interferon-
dependent immune responses. Nature 2005, 434, 772-777. 
65.  Honda, K.; Yanai, H.; Takaoka, A.; Taniguchi, T. Regulation of the type I IFN induction: a 
current view. Int. Immunol. 2005, 17, 1367-1378. 
66.  Hong, H.S.; Bhatnagar ,N.; Ballmaier, M.; Schubert, U.; Henklein, P.; Volgmann, T.; Heiken, 
H.; Schmidt, R.E.; Meyer-Olson, D. Exogenous HIV-1 Vpr disrupts IFN-α response by 
plasmacytoid dendritic cells (pDCs) and subsequent pDC/NK interplay. Immunol. Lett. 2009, 125, 
100-104. 
67.  Huthoff, H.; Towers, G.J. Restriction of retroviral replication by APOBEC3G/F and TRIM5α. 
Trends Microbiol. 2008, 16, 612-619. 
68.  Imbeault, M.; Ouellet, M.; Tremblay, M.J. Microarray study reveals that HIV-1 induces rapid 
type-I interferon-dependent p53 mRNA up-regulation in human primary CD4+ T cells. 
Retrovirology 2009, 6:5, pp. 14. 
69.  Jameson, P.; Essex, M. Inhibition of feline leukemia virus replication by human leukocyte 
interferon. Antiviral Res. 1983, 3, 115-120. 
70.  Jarrett,O. Strategies of retrovirus survival in the cat. Vet. Microbiol. 1999, 69, 99-107. Viruses 2009, 1                                       
 
 
568
71.  Juste, R.A.; Ott, T.L.; Kwang, J.; Bazer, F.W.; de la Concha-Bermejillo, A. Effects of 
recombinant interferon-tau on ovine lentivirus replication. J. Interferon Cytokine Res. 1996, 16, 
989-994. 
72.  Juste, R.A.; Ott, T.L.; Kwang, J.; Bazer, F.W.; de La Concha-Bermejillo, A. Effects of 
recombinant ovine interferon-tau on ovine lentivirus replication and progression of disease. J. 
Gen. Virol. 2000, 81, 525-532. 
73.  Kamga, I.; Kahi, S.; Develioglu, L.; Lichtner, M.; Marañón, C.; Deveau, C.; Meyer, L.; Goujard, 
C.; Lebon, P.; Sinet, M.; Hosmalin, A. Type I interferon production is profoundly and transiently 
impaired in primary HIV-1 infection. J. Infect. Dis. 2005, 192, 303-310. 
74.  Karpov, A.V. Endogenous and exogenous interferons in HIV-infection. Eur. J. Med. Res. 2001, 
6, 507-524. 
75.  Kawaguchi, Y; Norimine, J; Miyazawa, T; Kai, C; Mikami, T. Sequences within the feline 
immunodeficiency virus long terminal repeat that regulate gene expression and respond to 
activation by feline herpesvirus type 1. Virology 1992, 190, 465-468. 
76.  Keir, M.E.; Stoddart, C.A.; Linquist-Stepps, V.; Moreno, M.E.; McCune, J.M. IFN-α secretion 
by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J. Immunol. 
2002, 168, 325-331. 
77.  Keir, M.E.; Rosenberg, M.G.; Sandberg, J.K.; Jordan, K.A.; Wiznia, A.; Nixon, D.F.; Stoddart, 
C.A.; McCune, J.M. Generation of CD3+CD8low thymocytes in the HIV type 1-infected 
thymus. J. Immunol. 2002, 169, 2788-2796. 
78.  Kiermer, V.; Van Lint, C.; Briclet, D.; Vanhulle, C.; Kettmann, R.; Verdin, E.; Burny, A.; 
Droogmans, L. An interferon regulatory factor binding site in the U5 region of the bovine 
leukemia virus long terminal repeat stimulates Tax-independent gene expression. J. Virol. 1998, 
72, 5526-5534. 
79.  Kinpara, S.; Hasegawa, A.; Utsunomiya, A.; Nishitsuji, H.; Furukawa, H.; Masuda, T.; Kannagi, 
M. Stromal cell-mediated suppression of human T-cell leukemia virus type 1 expression in vitro 
and in vivo by type I interferon. J. Virol. 2009, 83, 5101-5108. 
80.  Kohara, J.; Yokomizo, Y. In vitro and in vivo effects of recombinant bovine interferon-tau on 
bovine leukemia virus. J. Vet. Med. Sci. 2007, 69, 15-19. 
81.  Kornbluth, R.S.; Oh, P.S.; Munis, J.R.; Cleveland, P.H.; Richman, D.D. Interferons and bacterial 
lipopolysaccharide protect macrophages from productive infection by human immunodeficiency 
virus in vitro. J. Exp. Med. 1989, 169, 1137-1151. 
82.  Künzi, M.S.; Pitha, P.M. Role of interferon-stimulated gene ISG-15 in the interferon-omega-
mediated inhibition of human immunodeficiency virus replication. J. Interferon Cytokine Res. 
1996, 16, 919-927. 
83.  Künzi, M.S.; Farzadegan, H.; Margolick, J.B.; Vlahov, D.; Pitha, P.M. Identification of human 
immunodeficiency virus primary isolates resistant to interferon-α and correlation of prevalence 
to disease progression. J. Infect. Dis. 1995, 171, 822-828. 
84.  Lehner, T.; Wang, Y.; Pido-Lopez, J.; Whittall, T.; Bergmeier, L.A.; Babaahmady, K. The 
emerging role of innate immunity in protection against HIV-1 infection. Vaccine 2008, 26, 2997-
3001. Viruses 2009, 1                                       
 
 
569
85.  Levy, D.E. Physiological significance of STAT proteins: investigations through gene disruption 
in vivo. Cell. Mol. Life Sci. 1999, 55, 1559-1567. 
86.  Levy, J.A.; Scott, I.; Mackewicz, C. Protection from HIV/AIDS: the importance of innate 
immunity. Clin. Immunol. 2003, 108, 167-174. 
87.  Lopez, C.; Fitzgerald, P.A.; Siegal, F.P. Severe acquired immune deficiency syndrome in male 
homosexuals: diminished capacity to make interferon-α  in vitro associated with severe 
opportunistic infections. J. Infect. Dis. 1983, 148, 962–966. 
88.  Luo, C.; Wang, K.; Liu de, Q.; Li, Y.; Zhao, Q.S. The functional roles of lipid rafts in T cell 
activation.; immune diseases and HIV infection and prevention. Cell. Mol. Immunol. 2008, 5, 1-
7. 
89.  Macchi, B.; Faraoni, I.; Mastino, A.; D'Onofrio, C.; Romeo, G.; Bonmassar, E. Protective effect 
of interferon beta on human T cell leukaemia virus type I infection of CD4+ T cells isolated from 
human cord blood. Cancer Immunol. Immunother. 1993, 37, 97-104. 
90.  Mandl, J.N.; Barry, A.P.; Vanderford, T.H.; Kozyr, N.; Chavan, R.; Klucking, S.; Barrat, F.J.; 
Coffman, R.L.; Staprans, S.I.; Feinberg, M.B. Divergent TLR7 and TLR9 signaling and type I 
interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 
2008, 14, 1077-1087. 
91.  Maneglier, B.; Rogez-Kreuz, C.; Dereuddre-Bosquet, N.; Martal, J.; Devillier, P.; Dormont, D.; 
Clayette, P. Anti-HIV effects of IFN-tau in human macrophages: role of cellular antiviral factors 
and interleukin-6. Pathol. Biol. (Paris) 2008, 56, 492-503. 
92.  Mangino, G.; Percario, Z.A.; Fiorucci, G.; Vaccari, G.; Manrique, S.; Romeo, G.; Federico, M.; 
Geyer, M.; Affabris, E. In vitro treatment of human monocytes/macrophages with myristoylated 
recombinant Nef of human immunodeficiency virus type 1 leads to the activation of mitogen-
activated protein kinases, IkappaB kinases, and interferon regulatory factor 3 and to the release 
of beta interferon. J. Virol. 2007, 81, 2777-2791. 
93.  Marchetti, M.; Monier, M.N.; Fradagrada, A.; Mitchell, K.; Baychelier, F.; Eid, P.; Johannes, L.; 
Lamaze, C. Stat-mediated signaling induced by type I and type II interferons (IFNs) is 
differentially controlled through lipid microdomain association and clathrin-dependent 
endocytosis of IFN receptors. Mol. Biol. Cell. 2006, 17, 2896-2909. 
94.  Marcondes, M.C.; Flynn, C.; Huitron-Rezendiz, S.; Watry, D.D.; Zandonatti, M.; Fox, H.S. 
Early antiretroviral treatment prevents the development of central nervous system abnormalities 
in simian immunodeficiency virus-infected rhesus monkeys. AIDS 2009, 23, 1187-1195. 
95.  Marié, I.; Durbin, J.E.; Levy, D.E. Differential viral induction of distinct interferon-α genes by 
positive feedback through interferon regulatory factor-7. EMBO J. 1998, 17, 6660-6669. 
96.  Marsili, G.; Borsetti, A.; Sgarbanti, M.; Remoli, A.L.; Ridolfi, B.; Stellacci, E.; Ensoli, B.; 
Battistini, A. On the role of interferon regulatory factors in HIV-1 replication. Ann. N Y Acad. 
Sci. 2003, 1010, 29-42. 
97.  Meylan, P.R.; Guatelli, J.C.; Munis, J.R.; Richman, D.D.; Kornbluth, R.S. Mechanisms for the 
inhibition of HIV replication by interferons-α, -beta, and -gamma in primary human 
macrophages. Virology 1993, 193, 138-148. Viruses 2009, 1                                       
 
 
570
98.  Mogensen, K.E.; Lewerenz, M.; Reboul, J.; Lutfalla, G.; Uzé, G. The type I interferon receptor: 
structure, function, and evolution of a family business. J. Interferon Cytokine Res. 1999, 19, 
1069-1098. 
99.  Munier, S.; Delcroix-Genête, D.; Carthagéna, L.; Gumez, A.; Hazan, U. Characterization of two 
candidate genes, NCoA3 and IRF8, potentially involved in the control of HIV-1 latency. 
Retrovirology 2005, 2, 73. 
100.  Murphy, F.A.; Gibbs, E.P.J.; Horzinek, M.C.; Studdert, M.J. Retroviridae. In Veterinary 
Virology 3
rd Ed. Academic Press: San Diego, USA; 1999; pp 363-389. 
101.  Niermann, G.L.; Buehring, G.C. Hormone regulation of bovine leukemia virus via the long 
terminal repeat. Virology 1997, 239, 249-258. 
102.  Oka, T.; Ohtsuki, Y.; Sonobe, H.; Furihata, M.; Miyoshi, I. Suppressive effects of interferons on 
the production and release of human T-lymphotropic virus type-I (HTLV-I). Arch. Virol. 1990, 
115, 63-73. 
103.  Okumura, A.; Lu, G.; Pitha-Rowe, I.; Pitha, P.M. Innate antiviral response targets HIV-1 release 
by the induction of ubiquitin-like protein ISG15. Proc. Natl. Acad. Sci. U S A. 2006, 103, 1440-
1445. 
104.  Pacanowski, J.; Kahi, S.; Baillet, M.; Lebon, P.; Deveau, C.;  Goujard, C.; Meyer, L.; 
Oksenhendler, E.; Sinet, M.; Hosmalin, A. Reduced blood CD123
+ (lymphoid) and CD11c
+ 
(myeloid) dendritic cell numbers in primary HIV-1 infection. Blood 2001, 98, 3016–3021. 
105.  Pacanowski, J.; Develioglu, L.; Kamga, I.; Sinet, M.; Desvarieux, M.; Girard, P. M.; Hosmalin, 
A. Early plasmacytoid dendritic cell changes predict plasma HIV load rebound during primary 
infection. J. Infect. Dis. 2004, 190, 1889–1892. 
106.  Pedretti, E.; Passeri, B.; Amadori, M.; Isola, P.; Di Pede, P.; Telera, A.; Vescovini, R.; 
Quintavalla, F.; Pistello, M. Low-dose interferon-α treatment for feline immunodeficiency virus 
infection. Vet. Immunol. Immunopathol. 2006, 109, 245-254. 
107.  Pestka, S.; Krause, C.D.; Walter, M.R. Interferons, interferon-like cytokines, and their receptors. 
Immunol. Rev. 2004, 202, 8-32. 
108.  Poli, G.; Orenstein, J.M.; Kinte,r A.; Folks, T.M.; Fauci, A.S. Interferon-α but not AZT 
suppresses HIV expression in chronically infected cell lines. Science 1989, 244, 575-577. 
109.  Pontzer, C.H.; Yamamoto, J.K.; Bazer, F.W.; Ott, T.L.; Johnson, H.M. Potent anti-feline 
immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J. Immunol. 
1997, 158, 4351-4357. 
110.  Quaranta, M.G.; Mattioli, B.; Giordani, L.; Viora, M. HIV-1 Nef equips dendritic cells to reduce 
survival and function of CD8+ T cells: a mechanism of immune evasion. FASEB J. 2004, 18, 
1459-1461. 
111.  Ramji, D.P; Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. 
Biochem. J. 2002, 365, 561-575. 
112.  Randall, R.E.; Goodbourn, S. Interferons and viruses: an interplay between induction, signalling, 
antiviral responses and virus countermeasures. J. Gen. Virol. 2008, 89, 1-47. 
113.  Rho, M.B.; Wesselingh, S.; Glass, J.D.; McArthur, J.C.; Choi, S.; Griffin, J.; Tyor, W.R. A 
potential role for interferon-α in the pathogenesis of HIV-associated dementia. Brain Behav. 
Immun. 1995, 9, 366-377. Viruses 2009, 1                                       
 
 
571
114.  Rogez, C.; Martin, M.; Dereuddre-Bosquet, N.; Martal, J.; Dormont, D.; Clayette, P. Anti-human 
immunodeficiency virus activity of tau interferon in human macrophages: involvement of 
cellular factors and beta-chemokines. J. Virol. 2003, 77, 12914-12920. 
115.  Rogez-Kreuz, C.; Manéglier, B.; Martin, M.; Dereuddre-Bosquet, N.; Martal, J.; Dormont, D.; 
Clayette, P. Involvement of IL-6 in the anti-human immunodeficiency virus activity of IFN-tau 
in human macrophages. Int. Immunol. 2005, 17, 1047-1057. 
116.  Rossol, S.; Voth, R.; Laubenstein, H.P.; Müller, W.E.; Schröder, H.C.; Meyer zum 
Büschenfelde, K.H.; Hess, G. Interferon production in patients infected with HIV-1. J. Infect. 
Dis. 1989, 159, 815-821. 
117.  Saito, M.; Nakagawa, M.; Kaseda, S.; Matsuzaki, T.; Jonosono, M.; Eiraku, N.; Kubota, R.; 
Takenouchi, N.; Nagai, M.; Furukawa, Y.; Usuku, K.; Izumo, S.; Osame, M. Decreased human T 
lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after 
interferon-α therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J. Infect. 
Dis. 2004, 189, 29-40. 
118.  Sakuma, R.; Mael, A.A.; Ikeda, Y. Α interferon enhances TRIM5α-mediated antiviral activities 
in human and rhesus monkey cells. J. Virol. 2007, 81, 10201-10206. 
119.  Samuel, C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 2001, 14, 778-809. 
120.  Sas, A.R.; Bimonte-Nelson, H.A.; Tyor, W.R. Cognitive dysfunction in HIV encephalitic SCID 
mice correlates with levels of Interferon-α in the brain. AIDS 2007, 21, 2151-2159. 
121.  Sas, A.R.; Bimonte-Nelson, H.; Smothers, C.T.; Woodward, J.; Tyor, W.R. Interferon-α causes 
neuronal dysfunction in encephalitis. J. Neurosci. 2009, 29, 3948-3955. 
122.  Schmidt, B.; Ashlock, B. M.; Foster, H.; Fujimura, S. H.; Levy, J. A. HIV-infected cells are 
major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. 
Virology 2005, 343, 256–266. 
123.  Severa, M.; Fitzgerald, K.A. TLR-mediated activation of type I IFN during antiviral immune 
responses: fighting the battle to win the war. Curr. Top. Microbiol. Immunol. 2007, 316, 167-
192. 
124.  Sgarbanti, M.; Borsetti, A.; Moscufo, N.; Bellocchi, MC.; Ridolfi, B.; Nappi, F.; Marsili, G.; 
Marziali, G.; Coccia, EM.; Ensoli, B.; Battistini, A. Modulation of human immunodeficiency 
virus 1 replication by interferon regulatory factors. J. Exp. Med. 2002, 195, 1359-1370. 
125.  Sgarbanti, M.; Marsili, G.; Remoli, A.L.; Ridolfi, B.; Stellacci, E.; Borsetti, A.; Ensoli, B.; 
Battistini, A. Analysis of the signal transduction pathway leading to human immunodeficiency 
virus-1-induced interferon regulatory factor-1 upregulation. Ann. N Y Acad. Sci. 2004, 1030, 
187-195. 
126.  Shirazi, Y.; Pitha, P.M. Α interferon inhibits early stages of the human immunodeficiency virus 
type 1 replication cycle. J. Virol. 1992, 66, 1321-1328. 
127.  Shirazi, Y.; Pitha, P.M. Interferon α-mediated inhibition of human immunodeficiency virus type 
1 provirus synthesis in T-cells. Virology 1993, 193, 303-312. 
128.  Short, J.A.L. Viral evasion of interferon stimulated genes. Bioscience Horizons  2009,  2,  
212-224. Viruses 2009, 1                                       
 
 
572
129.  Singh, B.; Ott, T.L.; Bazer, F.W.; de la Concha-Bermejillo, A. Phenotypic and ultrastructural 
characteristics of bronchoalveolar lavage cells of lentivirus-infected lambs treated with 
recombinant ovine IFN-tau. J. Interferon Cytokine Res. 2001, 21, 677-686. 
130.  Skalka, A.M.; Katz, R.A. Retroviral DNA integration and the DNA damage response. Cell Death 
Differ. 2005, Suppl 1, 971-978.  
131.  Smith, M.S.; Thresher, R.J.; Pagano, J.S. Inhibition of human immunodeficiency virus type 1 
morphogenesis in T cells by α interferon. Antimicrob. Agents Chemother. 1991, 35, 62-67. 
132.  Soumelis, V.; Scott, I.; Gheyas, F.; Bouhour, D.; Cozon, G.; Cotte, L.; Huang, L.;  Levy, J.A.; 
Liu, Y.J. Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS 
patients. Blood 2001, 98, 906–912. 
133.  Soumelis, V.; Scott, I.; Liu, Y.J.; Levy, J. Natural type 1 interferon producing cells in HIV 
infection. Hum. Immunol. 2002, 63, 1206-1212. 
134.  Sparger, E.E.; Shacklett, B.L.; Renshaw-Gegg, L.; Barry, P.A.; Pedersen, N.C.; Elder, J.H.; 
Luciw, P.A. Regulation of gene expression directed by the long terminal repeat of the feline 
immunodeficiency virus. Virology 1992, 187, 165-177. 
135.  Stark, G.R.; Kerr, I.M.; Williams, B.R.; Silverman, R.H.; Schreiber, R.D. How cells respond to 
interferons. Annu. Rev. Biochem. 1998, 67, 227-264. 
136.  Tanabe, T.; Yamamoto, J.K. Feline immunodeficiency virus lacks sensitivity to the antiviral 
activity of feline IFN-gamma. J. Interferon Cytokine Res. 2001, 21, 1039-46. 
137.  Taylor, M.D.; Korth, M.J.; Katze, M.G. Interferon treatment inhibits the replication of simian 
immunodeficiency virus at an early stage: evidence for a block between attachment and reverse 
transcription. Virology 1998, 241, 156-162. 
138.  Thompson, A.J.V.; Locarnini, S.A. Toll-like receptors, RIG-I-like RNA helicases and the 
antiviral innate immune response. Immunol. Cell. Biol. 2007, 85, 435-445. 
139.  Thompson, F.J.; Elder, J.; Neil, J.C. Cis- and trans-regulation of feline immunodeficiency virus: 
identification of functional binding sites in the long terminal repeat. J. Gen. Virol. 1994, 75,  
545-554. 
140.  Tilton, J.C.; Johnson, A.J.; Luskin, M.R.; Manion, M.M.; Yang, J.; Adelsberger, J.W.; Lempicki, 
R.A.; Hallahan, C.W.; McLaughlin, M.; Mican, J.M.; Metcalf, J.A.; Iyasere, C.; Connors, M. 
Diminished production of monocyte proinflammatory cytokines during human 
immunodeficiency virus viremia is mediated by type I interferons. J. Virol. 2006, 80, 11486-
11497. 
141.  Tilton, J.C.; Manion, M.M.; Luskin, M.R.; Johnson, A.J.; Patamawenu, A.A.; Hallahan, C.W.; 
Cogliano-Shutta, N.A.; Mican, J.M.; Davey, R.T. Jr.; Kottilil, S.; Lifson, J.D.; Metcalf, J.A.; 
Lempicki, R.A.; Connors, M. Human immunodeficiency virus viremia induces plasmacytoid 
dendritic cell activation in vivo and diminished α interferon production in vitro. J. Virol. 2008, 
82, 3997-4006. 
142.  Tsukahara, T.; Kim, S.; Taylor, M.W. REFINEMENT: a search framework for the identification 
of interferon-responsive elements in DNA sequences--a case study with ISRE and GAS. Comput. 
Biol. Chem. 2006, 30, 134-147. 
143.  Uematsu, S.; Akira, S. Toll-like receptors and type I interferons. J. Biol. Chem.  2007,  282, 
15319-15324. Viruses 2009, 1                                       
 
 
573
144.  Van Lint, C.; Amella, C.A.; Emiliani, S.; John, M.; Jie, T.; Verdin, E. Transcription factor 
binding sites downstream of the human immunodeficiency virus type 1 transcription start site are 
important for virus infectivity. J. Virol. 1997, 71, 6113-6127. 
145.  Vieillard, V.; Costagliola, D.; Simon, A.; Debré, P; French Asymptomatiques à Long Terme 
(ALT) Study Group. Specific adaptive humoral response against a gp41 motif inhibits CD4 T-
cell sensitivity to NK lysis during HIV-1 infection. AIDS 2006, 20, 1795-1804. 
146.  Williams, B.R. Transcriptional regulation of interferon-stimulated genes. Eur. J. Biochem. 1991, 
200, 1-11. 
147.  Yamamoto, J.K.; Ho, E.; Pedersen, N.C. A feline retrovirus induced T-lymphoblastoid cell-line 
that produces an atypical α type of interferon. Vet. Immunol. Immunopathol. 1986, 11, 1-19. 
148.  Yonezawa, A.; Morita, R.; Takaori-Kondo, A.; Kadowaki, N.; Kitawaki, T.; Hori, T.; Uchiyama, 
T. Natural α interferon-producing cells respond to human immunodeficiency virus type 1 with α 
interferon production and maturation into dendritic cells. J. Virol. 2003, 77, 3777–3784. 
149.  Zeidner, N.S.; Myles, M.H.; Mathiason-DuBard, C.K.; Dreitz, M.J.; Mullins, J.I.; Hoover, E.A. 
Α interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline 
leukemia virus-induced immunodeficiency syndrome. Antimicrob. Agents Chemother. 1990, 34, 
1749-1756. 
150.  Zhang, J.; Yamada, O.; Kawagishi, K.; Araki, H.; Yamaoka, S.; Hattori, T.; Shimotohno, K. 
Human T-cell leukemia virus type 1 Tax modulates interferon-α signal transduction through 
competitive usage of the coactivator CBP/p300. Virology 2008, 379, 306-313. 
 
© 2009 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. 
This article is an open-access article distributed under the terms and conditions of the Creative 
Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). 